Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsOlder adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.
A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.
A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
1.
Rising rates of head and neck cancers in England
2.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
3.
Treatment of Oligometastatic EGFR-Mutant Lung Cancer
4.
Cancer patients want financial screening early in care, study finds
5.
Mortality up for children with leukemia from lowest SES neighborhoods
1.
Colon Cancer Staging: What You Need to Know
2.
Unmasking the Subtle Symptoms of Colon Cancer
3.
All You Need to Know About Mesna: The Ultimate Guide
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
A Closer Look at Breast Cancer: Examining the Ultrasound Images
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge